fbpx
close read more
Videos

Oncology Commitment 2022: Claude Bertrand’s interview

04/02/2022

Oncology Commitment 2022: Claude Bertrand’s interview

For several years, Servier has been committed to developing treatments for cancers for which therapeutic needs are, for the most part, not yet covered and which are hard to treat, such as digestive, hematologic, and childhood cancers.

Focus on Servier’s oncology research with Claude Bertrand, Executive Vice President R&D.

Latest brochures and media

Brochures
25/05/2022
Brochures on the symptoms and treatment of depression
Videos
11/04/2022
Parkinson’s disease: Servier, a committed stakeholder
Videos
31/03/2022
Partnership Servier / Celsius Therapeutics